WikiCat
Buy Wiki Cat, it will reach 1 Billion Market cap.
Buy Wiki Cat, it will reach 1 Billion Market cap.
This company is the most underrated, undervalued company in all of the Russell 2000. I highly encourage you guys to look into the company.
$10 SPAC that’s currently trading at .60.
I’m long 50k shares, averaging up each time. I first found it after NVDA released an article on their Molecular Universe.
This is my “If it hits maybe I can retire early” play.
For a micro cap company, I am shocked at how financially disciplined the CEO is.
I actually work in the industry and this is my one high risk high reward play I have friends and family in.
Four revenue streams, all of which are growing in profits. Recent pivot away from EV and into Drones (YESSS)
ESS (Energy Storage Systems) 🔋
Residential/commercial energy-storage systems through UZ Energy.
SES provides the hardware plus battery-management / predictive-health software.
By far the biggest near-term revenue source. SES said roughly 65%+ of its 2026 $30–35M revenue guidance should come from ESS.
Drone / UAM batteries 🚁
High-energy-density Li-Metal and Li-ion cells for drones, defense drones, UAM and eventually robotics.
SES is converting manufacturing capacity in Korea to drone-format cells and pursuing NDAA-compliant production.
Expected to become much more important in the second half of 2026 and beyond.
Advanced battery materials 🧪
SES uses Molecular Universe to discover new electrolyte and other battery materials.
It can then sell those materials to battery companies/OEMs.
SES has discovered roughly six novel materials being tested by 40+ potential customers, with commercial-scale production expected through its Hisun JV.
Molecular Universe SaaS / AI4Science 🤖
Companies can pay for access to SES’s AI-powered molecular/material-discovery platform.
Think of it as software licensing/subscription revenue, rather than selling a physical battery.
Management says SaaS revenue is growing but will be a small contributor in 2026; the bigger current value is the IP and technology it feeds into the other businesses.
Blackrock recently purchased 18 million shares (Aug 3rd I think)
NO DEBT 160 million in cash. Revenue growing significantly, margins improving nicely, and battery OEMs and Drone / EVTOL. Recently got a deal with one of the bigger players in this space, proving commercial viability.
Please do your own DD and I guarantee you we’ll be Apes together. FORTUNE FAVORS THE BRAVE.
https://finance.yahoo.com/markets/stocks/articles/stonegate-updates-coverage-ses-ai-233400870.html
Every month we pull the trailing 1-year total return for every stock in our universe, rank them by market-cap tier, and publish the top performers. No opinions, no "buy this now" — just what actually happened, sorted plainly.
Why we do this differently: Most "top stocks" lists mix timeframes, cherry-pick lookback windows, or bury the methodology. Ours is simple: trailing 1-year total return (price + dividends), split by cap size (large/mid/small), recalculated on the same day every month.
Amazon gets 68% of its revenue from the US market in 2025.
Full split:
- US: 68%
- Germany: 6%
- UK: 6%
- Japan: 4%
- India: 2%
- Other: 4%
Quite concentrated for a global giant.
Full data: https://metricshour.com/stocks/amzn
What do you think about this exposure?
Every month we pull the trailing 1-year total return for every stock in our universe, rank them by market-cap tier, and publish the top performers. No opinions, no "buy this now" — just what actually happened, sorted plainly.
Why we do this differently: Most "top stocks" lists mix timeframes, cherry-pick lookback windows, or bury the methodology. Ours is simple: trailing 1-year total return (price + dividends), split by cap size (large/mid/small), recalculated on the same day every month.
$NAGE CEO spent the earnings call seeding a takeout narrative. 4 buyer universes:
🛒 CPG (Thorne/$PG $3.8B comp) → $NSRGY (Nestlé Health Science), $PG
💄 Beauty ("2 global skincare cos") → $LRLCY (L'Oréal)
💊 Pharma (Reata/$BIIB $7.3B comp) → $BIIB, for NB4168
📱 Telehealth → $HIMS
But: comp gated on $15 PSUs, so he's incentivized to talk his book. "In discussions" ≠ deal. No name, no LOI, no timeline. Real tell = a signed exclusive skincare supply deal w/ a named $LRLCY-tier buyer. Until then it's CEO optionality, not a catalyst
​
I’ve been spending a lot of time looking at small and mid-cap companies, trying to find businesses where the market may be underestimating the opportunity.
I’m particularly interested in companies that have:
• Significant upside potential
• A real catalyst within the next 6–12 months
• Improving revenue/profitability
• A strong balance sheet or improving financial position
• A valuation that still leaves room for upside
I’m not looking for meme stocks or companies that simply could 10x.
I’m more interested in finding businesses where the potential upside is supported by improving fundamentals.
One I’ve been researching recently is CorMedix ($CRMD), but I’m looking to expand the watchlist.
What small caps are you researching right now — and what's the actual thesis?
I'd love to hear some ideas and do some digging.
Every month we pull the trailing 1-year total return for every stock in our universe, rank them by market-cap tier, and publish the top performers. No opinions, no "buy this now" — just what actually happened, sorted plainly.
Why we do this differently: Most "top stocks" lists mix timeframes, cherry-pick lookback windows, or bury the methodology. Ours is simple: trailing 1-year total return (price + dividends), split by cap size (large/mid/small), recalculated on the same day every month. You can check our math.
Every month we pull the trailing 1-year total return for every stock in our universe, rank them by market-cap tier, and publish the top performers. No opinions, no "buy this now" — just what actually happened, sorted plainly.
Why we do this differently: Most "top stocks" lists mix timeframes, cherry-pick lookback windows, or bury the methodology. Ours is simple: trailing 1-year total return (price + dividends), split by cap size (large/mid/small), recalculated on the same day every month. You can check our math.
GRVY’s market cap is approximately $480 million from premarket trading. Its most recent cash balance is approximately $460 million at current KRW/USD exchange rate. The company also generated roughly $35 million of net profit in the first half of 2026!!!
So after adjusting for cash, the profitable operating business is being valued at almost nothing.
Why so cheap?
Because Gravity was a notorious cash hoarder. It accumulated cash for years without dividends, buybacks or a credible capital-deployment strategy. Investors reasonably applied a huge discount to cash they might never receive.
Today may be the inflection point.
Gravity announced:
Its first dividend since founding
KRW 4,400 per share
KRW 30.6 billion total distribution
$200 million allocated to growth and strategic investments
Shareholder returns as an explicit part of its capital-allocation framework
GungHo owns 59.3%, so governance remains a risk. But GungHo also became more shareholder-friendly this year, increasing its dividend, adopting a minimum 50% payout ratio and completing a JPY 5 billion buyback.
The discount existed because the cash looked permanently trapped. If management is now willing to return and deploy it, GRVY’s current valuation looks increasingly absurd.
Can anyone tell me more compelling stock to own?